T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
Humans
Lomustine
/ therapeutic use
Vincristine
/ therapeutic use
Oligodendroglioma
/ diagnostic imaging
Procarbazine
/ therapeutic use
Brain Neoplasms
/ diagnostic imaging
Retrospective Studies
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Neoplasm Recurrence, Local
Magnetic Resonance Imaging
PCV chemotherapy
anaplastic oligodendroglioma
pseudoprogression
radiotherapy
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
10
05
2023
received:
27
02
2023
accepted:
15
05
2023
medline:
8
8
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
ppublish
Résumé
Pseudoprogression in gliomas has been extensively described after radiotherapy with or without chemotherapy, but not after chemotherapy alone. Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone. We retrospectively reviewed the medical and radiological files of patients with 1p/19q codeleted, IDH-mutant anaplastic oligodendrogliomas treated with PCV chemotherapy alone who presented magnetic resonance imaging (MRI) modifications suggestive of tumour progression and in whom the final diagnosis was a pseudoprogression. We identified six patients. All patients underwent a surgical resection and were treated with PCV chemotherapy without radiotherapy. After a median of 11 months following the initiation of chemotherapy (range: 3-49 months), the patients developed asymptomatic white matter MRI modifications around the surgical cavity leading to the suspicion of a tumour progression. These modifications appeared as hyperintense on T2-fluid-attenuated inversion recovery (FLAIR) sequence, hypointense on T1 sequence, and lacked mass effect (0/6), contrast enhancement (0/6), restriction on diffusion-weighted imaging (0/4), relative cerebral blood volume (rCBV) increase on perfusion MRI (0/4), and hypermetabolism on Anaplastic oligodendroglioma patients treated with postoperative PCV chemotherapy alone occasionally develop T2/FLAIR hyperintensities around the surgical cavity that can wrongly suggest tumour progression. Multimodal imaging and close follow-up should be considered in this situation.
Sections du résumé
BACKGROUND
Pseudoprogression in gliomas has been extensively described after radiotherapy with or without chemotherapy, but not after chemotherapy alone. Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
METHODS
We retrospectively reviewed the medical and radiological files of patients with 1p/19q codeleted, IDH-mutant anaplastic oligodendrogliomas treated with PCV chemotherapy alone who presented magnetic resonance imaging (MRI) modifications suggestive of tumour progression and in whom the final diagnosis was a pseudoprogression.
RESULTS
We identified six patients. All patients underwent a surgical resection and were treated with PCV chemotherapy without radiotherapy. After a median of 11 months following the initiation of chemotherapy (range: 3-49 months), the patients developed asymptomatic white matter MRI modifications around the surgical cavity leading to the suspicion of a tumour progression. These modifications appeared as hyperintense on T2-fluid-attenuated inversion recovery (FLAIR) sequence, hypointense on T1 sequence, and lacked mass effect (0/6), contrast enhancement (0/6), restriction on diffusion-weighted imaging (0/4), relative cerebral blood volume (rCBV) increase on perfusion MRI (0/4), and hypermetabolism on
CONCLUSIONS
Anaplastic oligodendroglioma patients treated with postoperative PCV chemotherapy alone occasionally develop T2/FLAIR hyperintensities around the surgical cavity that can wrongly suggest tumour progression. Multimodal imaging and close follow-up should be considered in this situation.
Substances chimiques
Lomustine
7BRF0Z81KG
Vincristine
5J49Q6B70F
Procarbazine
35S93Y190K
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2879-2883Informations de copyright
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
de Wit MCY, de Bruin HG, Eijkenboom W, Sillevis Smitt PAE, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63(3):535-537. doi:10.1212/01.WNL.0000133398.11870.9A
van West SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, van den Bent MJ, Taal W. Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy. Neuro Oncol. 2017;19(5):719-725. doi:10.1093/neuonc/now194
Leao DJ, Craig PG, Godoy LF, Leite CC, Policeni B. Response assessment in neuro-oncology criteria for gliomas: practical approach using conventional and advanced techniques. AJNR Am J Neuroradiol. 2020;41(1):10-20. doi:10.3174/ajnr.A6358
Hernandez-Lain A, Hilario A, Sepulveda JM, Cantero D, Ramos A, Perez-Nuñez A. Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma. Neurology. 2016;87(1):114-115. doi:10.1212/WNL.0000000000002810
Sharma AM, Willcock M, Bucher O, et al. Institutional review of glial tumors treated with chemotherapy: the first description of PCV-related pseudoprogression. Neurooncol Pract. 2019;6(1):22-29. doi:10.1093/nop/npy012
Seyve A, Dehais C, Chinot O, et al. Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: a POLA network study. Neuro Oncol. 2022;25:495-507. doi:10.1093/neuonc/noac194
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1
Iwadate Y, Matsutani T, Hara A, et al. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. J Neurooncol. 2019;141(1):205-211. doi:10.1007/s11060-018-03027-5
Kearney H, Cryan J, Beausang A, Looby S, Brett FM. Reactive gliosis mimicking tumor recurrence - a case series documenting MRI abnormalities and neuropathological correlates. Clin Neuropathol. 2018;37(3):97-104. doi:10.5414/NP301084